Skip to main content

02 · Clinical Findings

Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity

MedPage Today1 min read

In a 68 week trial of 445 patients, weekly retatrutide injections cut WOMAC pain scores by over 4.4 points while helping participants lose more than a quarter of their body weight.

Image from the article by MedPage Today: Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity
Image: MedPage Today

In the 68-week TRIUMPH-4 trial of 445 patients with obesity and knee osteoarthritis, weekly retatrutide injections cut WOMAC pain scores by over 4.4 points versus 2.43 with placebo.

Targeting GLP-1, GIP, and glucagon receptors, the drug helped participants shed over a quarter of their body weight despite substantial baseline joint damage.

Authors in the New England Journal of Medicine noted that lighter knee loads and lower adipose inflammation may drive the relief, while calling for further study.

DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾

This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.

Related context

How this story connects across the peptide landscape.

Continue reading · Clinical FindingsPeptide News / Clinical FindingsGLP-1s confer better glycemic, CV outcomes than metforminHealio Endocrinology · Nov 6, 2026 · scroll to read